![2020 04 16 18 56 8041 Virus Coronavirus Sars Co V 2 400](https://img.labpulse.com/files/base/smg/all/image/2020/04/lp.2020_04_16_18_56_8041_virus_coronavirus_SARS-CoV-2_400.png?auto=format%2Ccompress&q=70&w=400)
ThermoGenesis Holdings has received an acknowledgement letter from the U.S. Food and Drug Administration (FDA) stating that its kit for the detection of antibodies to the SARS-CoV-2 virus has been appropriately validated.
The FDA letter means that ThermoGenesis can begin distributing the diagnostic kit, which detects the immunoglobulin M/immunoglobulin G (IgM/IgG) antibodies that result from infection with SARS-CoV-2, the virus that causes the COVID-19 respiratory disease.
The FDA acknowledgement was made under the terms of the FDA's March 16 announcement that allows companies to begin selling assays for SARS-CoV-2 before getting emergency use authorization (EUA) from the agency. The COVID-19 kit will be jointly marketed by ThermoGenesis and ImmuneCyte Life Sciences, according to the company.